April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
ILM peeling in diffuse diabetic macular edema non responsive to standard treatment. Updated findings
Author Affiliations & Notes
  • Anna Paola Salvetti
    Dpt of Clinical Science, Eye Clinic Sacco Hospital, Milano, Italy
  • Ferdinando Bottoni
    Dpt of Clinical Science, Eye Clinic Sacco Hospital, Milano, Italy
  • Matteo Giuseppe Cereda
    Dpt of Clinical Science, Eye Clinic Sacco Hospital, Milano, Italy
  • Luigi Bonavia
    Dpt of Clinical Science, Eye Clinic Sacco Hospital, Milano, Italy
  • Stefano de Angelis
    Dpt of Clinical Science, Eye Clinic Sacco Hospital, Milano, Italy
  • Mario V Cigada
    Dpt of Clinical Science, Eye Clinic Sacco Hospital, Milano, Italy
  • Giovanni Staurenghi
    Dpt of Clinical Science, Eye Clinic Sacco Hospital, Milano, Italy
  • Footnotes
    Commercial Relationships Anna Paola Salvetti, None; Ferdinando Bottoni, None; Matteo Cereda, None; Luigi Bonavia, None; Stefano de Angelis, None; Mario Cigada, None; Giovanni Staurenghi, Allergan, Inc. (C), Canon (S), Glaxo Smith Kline (C), Heidelberg Engineering (C), Ocular Instruments, Inc. (P), OD-OS (C), Optovue (S), Pfizer Ophthalmics (C), Zeiss (S)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 1162. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anna Paola Salvetti, Ferdinando Bottoni, Matteo Giuseppe Cereda, Luigi Bonavia, Stefano de Angelis, Mario V Cigada, Giovanni Staurenghi; ILM peeling in diffuse diabetic macular edema non responsive to standard treatment. Updated findings. Invest. Ophthalmol. Vis. Sci. 2014;55(13):1162.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: to evaluate the effect of 25 G pars plana vitrectomy (PPV) with internal limiting membrane (ILM) peeling in diabetic patients with clinicallly significant diffuse macular edema no more responsive to standard therapies.

Methods: retrospective analysis of visual acuity (VA), SD-OCT (HRA+OCT Spectralis, Heidelberg Engineering GmbH, Heidelberg, Germany) and fluorescein angiography images of 20 eyes of 20 vitrectomized patients with diagnosis of diabetic macular edema. Each patient was already submitted to intravitreal Bevacizumab and/or posterior pole laser treatment without success. Patients presenting at baseline with vitreomacular traction and/or microaneurisms suitable to laser treatment were excluded. 25 G pars plana vitrectomy with ILM peeling and cataract surgery when necessary were performed after 3 months wash-out. Operations were done by 3 different surgeons (FB, MC, SdeA). Selective Argon laser on peripheral areas of ischemia was performed during surgery if present. Mean preoperative VA and central retinal thickness (CRT) were compared to mean VA and CRT at 1, 3, 6, 9, and 12 months postop. The model was analyzed with Walter matrices (i.e., each dummy variable tests if VA and CRT changed significantly from the previous time point). Preoperative VA and CRT at T0 were used for the intercept. Predictive factors for anatomical and functional outcomes such as pre-op VA, CRT, presence of a posterior vitreous detachment, epiretinal membrane or IS-OS defect, were also investigated.

Results: No major complications occurred during and after surgeries.Visual acuity range was beetween 0,01 and 0,5 (Mean 0,18 +- 0,12) at baseline. Mean VA was 0,27 +-0,17 at 1 month, 0,32 +-0,2 at 3 months, 0,36 +-0,22 at 6, 0,36+-0.22 at 9 and 0,38 +-0.22 at 12 months follow-up. CRT was beetween 391 and 976 microns at baseline (Mean 645,2 +- 159,6). Mean CRT was 403 +- 114.4 microns at 1 month, 382 +-127 microns at 3, 352 +-123 microns at 6, 343.6+-129.9 microns at 9 and 337.1 +-126.5 microns at 12 months follow-up. The greatest reduction for both VA and CRT was beetween time 0 and 1.

Conclusions: PPV with ILM peeling is effective in diabetic patients with clinically significant macular edema no more responder to standard care to reduce retinal thickness and improve visual acuity. The only factor able to predict the reduction of CME was the presence of a PVD before surgery.

Keywords: 762 vitreoretinal surgery • 505 edema • 499 diabetic retinopathy  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×